Introduction
============

Breast carcinoma is the most common cancer diagnosed among women worldwide, with more than one in 10 new breast cancer cases occurring each year. After lung cancer, it is the second leading cause of cancer-related mortality among females ([@ref-6]; [@ref-9]). Moreover, metastatic disease, or the spread of tumor cells throughout the body, is responsible for the great majority of breast cancer patient deaths ([@ref-23]; [@ref-25]; [@ref-32]). It has been reported that about 20--30% of patients develop metastatic disease when diagnosed with early breast cancer ([@ref-7]; [@ref-27]). Breast cancer has a propensity for specific organs, most frequently bone and lung and in a lower extents, the liver and brain ([@ref-16]; [@ref-20]; [@ref-27]). A previous study showed that approximately 60% of breast cancer patients suffered lung or bone metastasis in their life ([@ref-10]).

Breast cancer lung metastatic patients have a median survival rate of only 22 months after treatment, indicating poor prognoses ([@ref-26]). It has been reported that 60--70% of breast cancer patients who eventually died were diagnosed with lung metastasis ([@ref-14]). Although a variety of available treatments for lung metastasis are being improved, such as radiotherapy, chemotherapy, or targeted therapy, the survival rate for lung metastatic patients remains very low. This seriously endangers the patient's quality of life and even life expectancy.

The main subtypes of breast cancer are divided by the expression statuses of three tumor markers evaluated comprehensively and routinely because of their application in guiding clinical treatment: estrogen receptor, progesterone receptor and human epidermal growth factor 2-neu (HER2). Among all breast cancers, approximately 75% of cases are classified as hormone receptor-positive (HR+; ER+ and/or the PR+) and HER2-negative ([@ref-12]) and the statuses of ER and PR are predicted by the response to endocrine therapy ([@ref-1]). HER2-positive cases represent 20% of breast cancers and show more aggressive clinical outcome because of restrictions on the application of chemotherapy ([@ref-4]). Additionally, triple negative breast cancers (TNBC), where there is an absence of ER, PR, and HRE2, account for 10--15% of all breast cancer cases. Compared with other breast cancer subtypes, TNBC is characterized by early relapse and aggressive behavior, with HER2-positive metastatic breast cancer specifically considered an incurable disease with the worst prognosis ([@ref-21]).

Metastatic breast cancer patients with various molecular subtypes have different clinical characteristics and prognoses, and the treatments they receive are also different. Patients with lung metastases account for a great proportion of metastatic breast cancer cases, and the influence of different tumor subtypes on the survival of lung metastatic patients is not clear. Therefore, it is necessary to analyze prognostic factors and survival outcomes for lung metastatic breast cancer patients in order to provide some basis for clinical treatment.

The purpose of this study was to use surveillance, epidemiology, and end results (SEER) population-based data to characterize the incidence of lung metastases at the time of initial diagnosis among stage IV breast cancer patients. We also assessed related risk factors and survival outcomes to improve the prognosis of lung metastatic breast cancer and reduce the occurrence of lung metastasis.

Materials and Methods
=====================

Data source and study design
----------------------------

The population-based data were obtained from SEER, and included cancer incidence and survival data from 18 registries. Within the SEER database, we extracted 379,261 patients who were diagnosed with breast cancer between 1st January 2010 and 31st December 2015. We then generated a cohort of 21,435 stage IV breast cancer patients. Of these, 6,516 patients were diagnosed with lung metastases. We excluded patients who were diagnosed at autopsy or by death certificate, as well as patients whose follow-up times were unknown. Finally, we identified 5,760 patients eligible for survival analysis. This study was exempted by the Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong University, because all data extracted from the publicly available SEER database were free and recognized as nonhuman studies ([@ref-5]; [@ref-31]).

Patients were classified by breast cancer molecular subtypes: HR-positive/HER2-negative (HR+/HER2−), HR-positive/HER2-positive (HR+/HER2+), HR-negative/HER2-positive (HR−/HER2+) and triple-negative (HR-negative/HER2-negative). Study variables included age at diagnosis, gender, race, marital status, tumor sites, tumor grade, histology, number of other metastatic sites, surgery, radiation therapy, chemotherapy, and vital status. Other sites of metastasis were defined as different metastasis at initial diagnosis of bone, liver, or brain.

Statistical analysis
--------------------

Clinical characteristics of the different subtypes were compared with chi-square or Fisher's exact tests. We used the Kaplan--Meier method to estimate survival probabilities and to generate survival curves within various subtypes and the number of other metastatic sites. A Cox proportional hazards regression was conducted to identify the independent association of variables with overall survival (OS) and BCSS in lung metastatic patients. Hazard ratios and 95% confidence intervals (95% CIs) were calculated using the Cox model. All *P* values of 0.05 or less were considered statistically significant, and *P* values were two-tailed. Statistical analyses were performed using SPSS statistical software (version 24.0; IBM Corporation, Armonk, NY, USA).

Results
=======

Incidence
---------

A total of 379,261 patients diagnosed with breast cancer were classified by different subtypes to analyze incidence and median survival between 2010 and 2015 ([Table 1](#table-1){ref-type="table"}). The incidence proportions of HR+/HER2−, HR+/HER2+, HR−/HER2+, triple-negative and unknown subtype were 66.9%, 9.6%, 4.1%, 10.3% and 9.0%, respectively. Among the 21,435 patients with metastatic disease at any site (bone, lung, liver, brain), 50.9%, 13.4%, 7.3%, 11.5% and 16.9% had HR+/HER2−, HR+/HER2+, HR−/HER2+, triple-negative and unknown subtype, respectively. In the entire cohort, the 6,516 patients diagnosed with lung metastases accounted for 1.7% of the entire cohort, and 30.4% of the subset with metastatic disease. Of these, the incidence proportions were higher among patients with HR−/HER2+ molecular subtype (3.5% of the entire cohort and 35.1% of the metastatic subgroup) and triple-negative subtype (2.5% of the entire cohort and 39.7% of the metastatic subgroup).
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###### The incidence proportion and median survival of breast cancer patients with lung metastases stratified by subtypes.
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  --------------------------------------------------------------------------------------------------------------------------------------------------
  Subtypes          Patients No.   Incidence proportion of lung metastases, %   Survival among patients with lung\                
                                                                                metastases, median (IQR), months                  
  ----------------- -------------- -------------------------------------------- ------------------------------------ ----- ------ ------------------
  HR+/HER2−         253,783        10,909                                       2,940                                1.2   27.0   16.0 (6.0--31.0)

  HR+/HER2+         36,458         2,872                                        852                                  2.3   29.7   17.0 (7.0--31.0)

  HR−/HER2+         15,727         1,557                                        547                                  3.5   35.1   12.0 (5.0--25.0)

  Triple-negative   39,147         2,473                                        983                                  2.5   39.7   8.0 (3.0--16.0)

  Unknown           34,146         3,624                                        1,194                                3.5   32.9   8.0 (2.0--22.0)

  All subtypes      379,261        21,435                                       6,516                                1.7   30.4   13.0 (5.0--27.0)
  --------------------------------------------------------------------------------------------------------------------------------------------------

We assessed the distribution of clinical characteristics of lung metastatic patients according to their molecular subtypes. There were significant differences among the entire cohort ([Table 2](#table-2){ref-type="table"}). The lung metastatic patients from the HR+/HER2− subtype showed older age at diagnosis (*P* \< 0.001), lower-grade tumors (*P* \< 0.001), high proportions of lobular histology (*P* \< 0.001) and two metastatic sites at initial diagnosis (*P* \< 0.001). Patients with the HR+/HER2+ subtype had high proportions of ductal histology (*P* \< 0.001), three metastatic sites at initial diagnosis (*P* \< 0.001) and more survivors (*P* \< 0.001). The HR−/HER2+ cases were aged younger at diagnosis (*P* \< 0.001), had four metastatic sites at initial diagnosis (*P* \< 0.001) and high proportions of undergoing chemotherapy (*P* \< 0.001). Patients with triple-negative subtype, by contrast, had higher-grade tumors (*P* \< 0.001) and higher proportions of receiving surgery and radiation (*P* \< 0.001). The triple-negative patients also had higher rates of lung metastases and poorer survival rates (*P* \< 0.001).
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###### The clinical characteristics of patients with lung metastases according to tumor subtypes.
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  Patients characteristics                                             Tumor subtypes   *P* value                                                            
  -------------------------------------------------------------------- ---------------- ------------ ------------ ------------ -------------- -------------- ---------
  All patients                                                         2,940 (45.1)     852 (13.1)   547 (8.4)    983 (15.1)   1,194 (18.3)   6,516 (100)    
  **Age at diagnosis, years**                                                                                                                                \<0.001
  18--40                                                               137 (4.7)        62 (7.3)     51 (9.3)     75 (7.6)     33 (2.8)       358 (5.5)      
  41--60                                                               977 (33.2)       370 (43.4)   255 (46.6)   369 (37.5)   326 (27.3)     2,297 (35.3)   
  61--80                                                               1,465 (49.8)     340 (39.9)   197 (36.0)   419 (42.6)   538 (45.1)     2,959 (45.4)   
  \>80                                                                 361 (12.3)       80 (9.4)     44 (8.0)     120 (12.2)   297 (24.9)     902 (13.8)     
  **Gender**                                                                                                                                                 0.052
  Male                                                                 54 (1.8)         16 (1.9)     2 (0.4)      8 (0.8)      18 (1.5)       98 (1.5)       
  Female                                                               2,886 (98.2)     836 (98.1)   545 (99.6)   975 (99.2)   1,176 (98.5)   6,418 (98.5)   
  Race                                                                                                                                                       \<0.001
  White                                                                2,168 (73.7)     627 (73.6)   378 (69.1)   646 (65.7)   910 (76.2)     4,729 (72.6)   
  Black                                                                508 (17.3)       151 (17.7)   107 (19.6)   260 (26.4)   207 (17.3)     1,233 (18.9)   
  Other                                                                253 (8.6)        72 (8.5)     60 (11.0)    76 (7.7)     70 (5.9)       531 (8.1)      
  Unknown                                                              11 (0.4)         2 (0.2)      2 (0.4)      1 (0.1)      7 (0.6)        23 (0.4)       
  **Marital status**                                                                                                                                         0.033
  Single                                                               678 (23.1)       193 (22.7)   116 (21.2)   209 (21.3)   289 (24.2)     1,485 (22.8)   
  Married/domestic partner                                             1,132 (38.5)     363 (42.6)   223 (40.8)   390 (39.7)   396 (33.2)     2,504 (38.4)   
  Divorced/separated/widowed                                           958 (32.6)       251 (29.5)   170 (31.1)   329 (33.5)   433 (36.3)     2,141 (32.9)   
  Unknown                                                              172 (5.9)        45 (5.3)     38 (6.9)     55 (5.6)     76 (6.4)       386 (5.9)      
  **Tumor site(s)**                                                                                                                                          \<0.001
  Only one site (left or right)                                        2,853 (97.0)     837 (98.2)   531 (97.1)   958 (97.5)   1,050 (87.9)   6,229 (95.6)   
  Two or more sites                                                    87 (3.0)         15 (1.8)     16 (2.9)     25 (2.5)     144 (12.1)     287 (4.4)      
  **Tumor grade**                                                                                                                                            \<0.001
  I                                                                    228 (7.8)        20 (2.3)     1 (0.2)      9 (0.9)      23 (1.9)       281 (4.3)      
  II                                                                   1,191 (40.5)     274 (32.2)   90 (16.5)    110 (11.2)   166 (13.9)     1,831 (28.1)   
  III                                                                  937 (31.9)       424 (49.8)   347 (63.4)   702 (71.4)   197 (16.5)     2,607 (40.0)   
  IV                                                                   16 (0.5)         7 (0.8)      9 (1.6)      14 (1.4)     11 (0.9)       57 (0.9)       
  Unknown                                                              568 (19.3)       127 (14.9)   100 (18.3)   148 (15.1)   797 (66.8)     1,740 (26.7)   
  **Histology**                                                                                                                                              \<0.001
  Ductal                                                               2,176 (74.0)     700 (82.2)   434 (79.3)   726 (73.9)   418 (35.0)     4,455 (68.4)   
  Lobular                                                              176 (6.0)        13 (1.5)     2 (0.4)      11 (1.1)     37 (3.1)       239 (3.7)      
  Mixed ductal and lobular                                             165 (5.6)        37 (4.3)     11 (2.0)     20 (2.0)     19 (1.6)       252 (3.9)      
  Mucinous                                                             52 (1.8)         5 (0.6)      0 (0)        1 (0.1)      5 (0.4)        63 (1.0)       
  Carcinoma                                                            371 (12.6)       97 (11.4)    100 (18.3)   224 (22.8)   715 (59.9)     1,507 (23.1)   
  **Extrapulmonary metastatic sites to bone, brain, and liver, No.**                                                                                         \<0.001
  0                                                                    831 (28.3)       259 (30.4)   212 (38.8)   448 (45.6)   394 (33.0)     2,144 (32.9)   
  1                                                                    1,420 (48.3)     314 (36.9)   159 (29.1)   339 (34.5)   470 (39.4)     2,702 (41.5)   
  2                                                                    587 (20.0)       241 (28.3)   136 (24.9)   144 (14.6)   257 (21.5)     1,365 (20.9)   
  All 3                                                                87 (3.0)         36 (4.2)     37 (6.8)     43 (4.4)     36 (3.0)       239 (3.7)      
  Unknown                                                              15 (0.5)         2 (0.2)      3 (0.5)      9 (0.9)      37 (3.1)       66 (1.0)       
  **Cancer-directed surgery**                                                                                                                                \<0.001
  Performed                                                            583 (19.8)       212 (24.9)   168 (30.7)   332 (33.8)   123 (10.3)     1,418 (21.8)   
  Not performed                                                        2,307 (78.5)     627 (73.6)   366 (66.9)   635 (64.6)   1,043 (87.4)   4,978 (76.4)   
  Unknown                                                              50 (1.7)         13 (1.5)     13 (2.4)     16 (1.6)     28 (2.3)       120 (1.8)      
  **Radiation**                                                                                                                                              \<0.001
  Yes                                                                  790 (26.9)       220 (25.8)   150 (27.4)   279 (28.4)   156 (13.1)     1,595 (24.5)   
  No                                                                   2,107 (71.7)     616 (72.3)   385 (70.4)   687 (69.9)   1,034 (86.6)   4,829 (74.1)   
  Unknown                                                              42 (1.4)         16 (1.9)     12 (2.2)     17 (1.7)     4 (0.3)        91 (1.4)       
  **Chemotherapy**                                                                                                                                           \<0.001
  Yes                                                                  1,241 (42.2)     610 (71.6)   410 (75.0)   683 (69.5)   304 (25.5)     3,248 (49.8)   
  No/unknown                                                           1,699 (57.8)     242 (28.4)   137 (25.0)   300 (30.5)   890 (74.5)     3,268 (50.2)   
  **Status**                                                                                                                                                 \<0.001
  Alive                                                                1,335 (45.4)     460 (54.0)   245 (44.8)   230 (23.4)   254 (21.3)     2,524 (38.7)   
  Dead                                                                 1,605 (54.6)     392 (46.0)   302 (55.2)   753 (76.6)   940 (78.7)     3,992 (61.3)   
  **Cause of death**                                                                                                                                         \<0.001
  Alive                                                                1,335 (45.4)     460 (54.0)   245 (44.8)   230 (23.4)   254 (21.3)     2,524 (38.7)   
  Breast cancer                                                        1,357 (46.2)     343 (40.3)   261 (47.7)   669 (68.1)   740 (62.0)     3,370 (51.7)   
  Other                                                                248 (8.4)        49 (5.8)     41 (7.5)     84 (8.5)     200 (16.8)     622 (9.5)      

Survival
--------

The median survival among lung metastatic patients was 13 months, and the 3-year and 5-year survival rates of these patients were 33.9% and 17.8%, respectively ([Fig. 1](#fig-1){ref-type="fig"}). Among the four subtypes shown in [Fig. 2](#fig-2){ref-type="fig"}, patients with the HR+/HER2+ subtype had the longest median survival (17 months), and their 3-year and 5-year survival rates were 45.4% and 30.2%, respectively. Triple-negative subtypes had the shortest median survival (8 months), and their 3-year and 5-year survival rates were 10.9% and 5.6%, respectively. Moreover, an exploratory analysis of OS according to the number of metastatic tumor sites showed significant differences among lung metastatic patients. The cases with only lung metastases had longer median survival (15 months) compared with patients with four metastasis sites at initial diagnosis (6 months). The 3-year survival rate of patients with only lung metastases and four metastasis sites were 40.1% and 17.1%, and the 5-year survival rate of these were 22.3% and 9.8%, respectively ([Fig. 3](#fig-3){ref-type="fig"}).

![The overall survival for the patients with lung metastases from breast cancer, and the table showing the number at risk for overall survival.](peerj-07-8298-g001){#fig-1}

![The overall survival according to tumor subtype, and the table showing the number at risk for tumor subtype.\
Log-rank *P* \< 0.0001. HR, hormone receptor; HER2, human epidermal growth factor receptor 2.](peerj-07-8298-g002){#fig-2}

![The overall survival stratified by the extent of extrapulmonary metastatic disease, and the table showing the number at risk according to number of metastasis sites.\
Log-rank *P* \< 0.0001.](peerj-07-8298-g003){#fig-3}

We used a Cox proportional hazards model to investigate prognostic factors for OS and BCSS using univariate and multivariate analysis. In the univariate model for OS, patients with poor prognoses were older (age \>80; HR, 2.418; (95% CI \[2.022--2.893\]); *P* \< 0.001), black (HR, 1.253; (95% CI \[1.152--1.363\]); *P* \< 0.001), had tumor grade III (HR, 1.890; (95% CI \[1.557--2.294\]); *P* \< 0.001), were triple-negative subtype (HR, 2.353; (95% CI \[2.145--2.581\]); *P* \< 0.001) and had four metastasis sites at initial diagnosis (HR, 2.345; (95% CI \[1.972--2.790\]); *P* \< 0.001). BCSS results were consistent with those for OS ([Table 3](#table-3){ref-type="table"}). Furthermore, using multivariate analysis, we found that the dependent prognostic factors for OS were older age, black race, tumor grade III, triple-negative subtype, having four metastasis sites at initial diagnosis, non-surgery, and not receiving chemotherapy. The results for BCSS exhibited a similar trend ([Table 4](#table-4){ref-type="table"}).
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###### Unadjusted overall survival and breast cancer-specific survival.
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  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                             Survival, median\   Overall survival   Breast cancer-specific survival                                                
                                                                       (IQR), months                                                                                                         
  -------------------------------------------------------------------- ------------------- ------------------ --------------------------------- --------- --------- ------------------------ ---------
  **Age at diagnosis, years**                                                                                                                                                                

  18--40                                                               18.0 (8.0--30.0)    \<0.001            Reference                                   \<0.001   Reference                

  41--60                                                               15.0 (6.0--29.0)                       1.236 \[1.045--1.461\]            0.013               1.243 \[1.040--1.485\]   0.017

  61--80                                                               13.0 (4.0--27.0)                       1.454 \[1.233--1.715\]            \<0.001             1.379 \[1.157--1.644\]   \<0.001

  \>80                                                                 7.0 (2.0--18.0)                        2.418 \[2.022--2.893\]            \<0.001             2.111 \[1.741--2.561\]   \<0.001

  **Sex**                                                                                                                                                                                    

  Male                                                                 17.0 (4.0--32.0)    0.059              Reference                                   0.016     Reference                

  Female                                                               13.0 (5.0--27.0)                       1.324 \[0.983--1.783\]            0.065               1.508 \[1.070--2.126\]   0.019

  **Race**                                                                                                                                                                                   

  White                                                                13.0 (5.0--28.0)    \<0.001            Reference                                   \<0.001   Reference                

  Black                                                                12.0 (4.0--24.0)                       1.253 \[1.152--1.363\]            \<0.001             1.262 \[1.153--1.383\]   \<0.001

  Other                                                                14.0 (5.0--28.0)                       0.880 \[0.770--1.004\]            0.058               0.851 \[0.736--0.985\]   0.030

  **Marital status**                                                                                                                                                                         

  Single                                                               13.0 (4.0--27.0)    \<0.001            Reference                                   \<0.001   Reference                

  Married/domestic partner                                             15.0 (6.0--30.0)                       0.768 \[0.702--0.840\]            \<0.001             0.781 \[0.709--0.860\]   \<0.001

  Divorced/separated/widowed                                           10.0 (4.0--23.0)                       1.134 \[1.036--1.240\]            0.006               1.097 \[0.995--1.209\]   0.063

  **Tumor site(s)**                                                                                                                                                                          

  Only one site (left or right)                                        13.0 (5.0--27.0)    \<0.001            Reference                                   0.073     Reference                

  Two or more sites                                                    8.0 (2.0--22.0)                        1.346 \[1.138--1.591\]            0.001               1.189 \[0.981--1.441\]   0.078

  **Tumor grade**                                                                                                                                                                            

  I                                                                    18.0 (6.0--32.0)    \<0.001            Reference                                   \<0.001   Reference                

  II                                                                   17.0 (6.0--31.0)                       1.247 \[1.023--1.521\]            0.029               1.310 \[1.049--1.634\]   0.017

  III                                                                  12.0 (5.0--25.0)                       1.890 \[1.557--2.294\]            \<0.001             2.100 \[1.692--2.606\]   \<0.001

  IV                                                                   14.0 (4.0--28.0)                       1.785 \[1.204--2.646\]            0.004               1.954 \[1.277--2.990\]   0.002

  **Histology**                                                                                                                                                                              

  Ductal                                                               14.0 (5.0--28.0)    \<0.001            Reference                                   \<0.001   Reference                

  Lobular                                                              18.0 (6.0--30.0)                       1.048 \[0.879--1.249\]            0.603               1.020 \[0.843--1.234\]   0.603

  Mixed ductal and lobular                                             18.0 (7.0--33.0)                       0.782 \[0.652--0.939\]            0.009               0.764 \[0.627--0.931\]   0.008

  Mucinous                                                             16.0 (5.0--34.0)                       0.658 \[0.440--0.983\]            0.041               0.629 \[0.405--0.978\]   0.629

  Carcinoma                                                            8.0 (3.0--21.0)                        1.563 \[1.441--1.694\]            \<0.001             1.438 \[1.315--1.573\]   \<0.001

  **Tumor subtype**                                                                                                                                                                          

  HR+/HER2−                                                            16.0 (6.0--31.0)    \<0.001            Reference                                   \<0.001   Reference                

  HR+/HER2+                                                            17.0 (7.0--31.0)                       0.821 \[0.730--0.923\]            0.001               0.847 \[0.747--0.960\]   0.009

  HR−/HER2+                                                            12.0 (5.0--25.0)                       1.171 \[1.026--1.337\]            0.019               1.184 \[1.026--1.336\]   0.021

  Triple-negative                                                      8.0 (3.0--16.0)                        2.353 \[2.145--2.581\]            \<0.001             2.478 \[2.245--2.736\]   \<0.001

  **Extrapulmonary metastatic sites to bone, brain, and liver, No.**                                                                                                                         

  0                                                                    15.0 (6.0--28.0)    \<0.001            Reference                                   \<0.001   Reference                

  1                                                                    14.0 (5.0--28.0)                       1.153 \[1.063--1.251\]            0.001               1.199 \[1.097--1.310\]   \<0.001

  2                                                                    10.0 (3.0--23.0)                       1.654 \[1.506--1.818\]            \<0.001             1.771 \[1.599--1.960\]   \<0.001

  All 3                                                                6.0 (2.0--16.0)                        2.345 \[1.972--2.790\]            \<0.001             2.411 \[1.996--2.913\]   \<0.001

  **Cancer-directed surgery**                                                                                                                                                                

  Performed                                                            19.0 (8.0--34.0)    \<0.001            Reference                                   \<0.001   Reference                

  Not performed                                                        11.0 (4.0--25.0)                       1.613 \[1.484--1.754\]            \<0.001             1.557 \[1.424--1.703\]   \<0.001

  **Radiation**                                                                                                                                                                              

  Yes                                                                  14.0 (5.0--28.0)    0.640              Reference                                   0.716     Reference                

  No                                                                   13.0 (4.0--27.0)                       1.018 \[0.943--1.099\]            0.647               0.985 \[0.908--1.069\]   0.721

  **Chemotherapy**                                                                                                                                                                           

  Yes                                                                  15.0 (6.0--28.0)    \<0.001            Reference                                   \<0.001   Reference                

  No/unknown                                                           11.0 (3.0--25.0)                       1.424 \[1.331--1.524\]            \<0.001             1.321 \[1.227--1.422\]   \<0.001
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### Multivariate analysis overall survival and breast cancer-specific survival.
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  Variable                                                             Overall survival         Breast cancer-specific survival                            
  -------------------------------------------------------------------- ------------------------ --------------------------------- ------------------------ ---------
  **Age at diagnosis, years**                                                                                                                              
  18--40                                                               Reference                                                  Reference                
  41--60                                                               1.236 \[1.012--1.509\]   0.038                             1.277 \[1.034--1.577\]   0.023
  61--80                                                               1.491 \[1.217--1.825\]   \<0.001                           1.479 \[1.193--1.832\]   \<0.001
  \>80                                                                 2.189 \[1.720--2.784\]   \<0.001                           2.107 \[1.628--2.727\]   \<0.001
  **Sex**                                                                                                                                                  
  Male                                                                 Reference                                                  Reference                
  Female                                                               1.177 \[0.808--1.715\]   0.397                             1.306 \[0.855--1.996\]   0.217
  **Race**                                                                                                                                                 
  White                                                                Reference                                                  Reference                
  Black                                                                1.246 \[1.112--1.397\]   \<0.001                           1.221 \[1.081--1.379\]   0.001
  Other                                                                0.982 \[0.836--1.154\]   0.829                             0.943 \[0.792--1.123\]   0.509
  **Marital status**                                                                                                                                       
  Single                                                               Reference                                                  Reference                
  Married/domestic partner                                             0.805 \[0.717--0.905\]   \<0.001                           0.794 \[0.702--0.898\]   \<0.001
  Divorced/separated/widowed                                           1.048 \[0.928--1.185\]   0.449                             1.020 \[0.895--1.162\]   0.764
  **Tumor site(s)**                                                                                                                                        
  Only one site (left or right)                                        Reference                                                  Reference                
  Two or more sites                                                    1.584 \[0.976--2.572\]   0.063                             1.733 \[1.051--2.857\]   0.031
  **Tumor grade**                                                                                                                                          
  I                                                                    Reference                                                  Reference                
  II                                                                   1.301 \[1.044--1.620\]   0.019                             1.374 \[1.075--1.756\]   0.011
  III                                                                  1.865 \[1.492--2.330\]   \<0.001                           2.070 \[1.615--2.652\]   \<0.001
  IV                                                                   1.635 \[1.037--2.580\]   0.034                             1.796 \[1.099--2.934\]   0.019
  **Histology**                                                                                                                                            
  Ductal                                                               Reference                                                  Reference                
  Lobular                                                              0.913 \[0.714--1.169\]   0.471                             0.922 \[0.708--1.202\]   0.55
  Mixed ductal and lobular                                             1.056 \[0.860--1.298\]   0.603                             1.058 \[0.847--1.322\]   0.617
  Mucinous                                                             0.765 \[0.439--1.332\]   0.343                             0.763 \[0.418--1.394\]   0.379
  Carcinoma                                                            1.412 \[1.218--1.636\]   \<0.001                           1.364 \[1.165--1.598\]   \<0.001
  **Tumor subtype**                                                                                                                                        
  HR+/HER2−                                                            Reference                                                  Reference                
  HR+/HER2+                                                            0.906 \[0.786--1.045\]   0.175                             0.914 \[0.786--1.063\]   0.244
  HR−/HER2+                                                            1.272 \[1.073--1.508\]   0.005                             1.232 \[1.027--1.478\]   0.025
  Triple-negative                                                      2.766 \[2.436--3.140\]   \<0.001                           2.872 \[2.510--3.285\]   \<0.001
  **Extrapulmonary metastatic sites to bone, brain, and liver, No.**                                                                                       
  0                                                                    Reference                                                  Reference                
  1                                                                    1.477 \[1.323--1.649\]   \<0.001                           1.512 \[1.344--1.702\]   \<0.001
  2                                                                    2.429 \[2.137--2.760\]   \<0.001                           2.489 \[2.171--2.853\]   \<0.001
  All 3                                                                3.833 \[3.022--4.862\]   \<0.001                           3.950 \[3.072--5.080\]   \<0.001
  **Cancer-directed surgery**                                                                                                                              
  Performed                                                            Reference                                                  Reference                
  Not performed                                                        1.541 \[1.389--1.710\]   \<0.001                           1.519 \[1.360--1.697\]   \<0.001
  **Radiation**                                                                                                                                            
  Yes                                                                  Reference                                                  Reference                
  No                                                                   1.047 \[0.949--1.154\]   0.362                             1.047 \[0.943--1.162\]   0.393
  **Chemotherapy**                                                                                                                                         
  Yes                                                                  Reference                                                  Reference                
  No/unknown                                                           1.457 \[1.313--1.618\]   \<0.001                           1.420 \[1.270--1.588\]   \<0.001

Discussion
==========

Lung metastasis is the most frequent type of breast cancer metastasis after bone metastasis. Few symptoms usually emerge until after the lungs have been replaced by metastatic tumor cells ([@ref-22]; [@ref-32]). Because it is difficult to discover from the surface, lung metastasis has been a huge challenge in the treatment of breast cancer patients. On account of the particularity of breast cancer, treatments are different based on the various molecular subtypes ([@ref-26]). Current treatment strategies, including surgical resection, chemotherapy and/or radiotherapy, provide relief rather than cure, especially for patients diagnosed with Stage IV disease ([@ref-23]). In this study, lung metastatic patients diagnosed initially with breast cancer were classified by different tumor subtypes, and their incidence and dependent prognostic factors were explored. We identified 6,516 patients with lung metastases with initially diagnosed breast cancer, accounting for 1.7% of the entire cohort and 30.4% of metastatic disease subgroups, respectively. Similarly, [@ref-24] reported that lung metastases accounted for 31.4% of all metastases in breast cancer. Our results suggested that the incidence proportion of lung metastases was higher among patients with triple-negative and HR−/HER2+ subtypes. The incidence of lung metastasis was also shown to reach up to 40% in triple-negative breast cancer compared with only 20% in non-triple-negative breast cancer, and our results were similar to previous studies ([@ref-14]; [@ref-15]; [@ref-27]).

In the present study, median survival from breast cancer diagnoses obviously varied by subtype, ranging from 8 months in triple-negative patients to 17 months in HR+/HER2+ patients. The median survival of all lung metastatic patients was 13 months, which was shorter than the 22 or 32 months reported in lung metastatic patients after treatment or metastasectomy in previous studies ([@ref-14]; [@ref-19]; [@ref-30]). Although patients with lung metastases had poor prognoses, it was noteworthy that the 3-year and 5-year survival rate of patients was up to 33.9% and 17.8%, respectively. Prior studies have shown that the 5-year survival rate of lung metastatic patients from the first pulmonary metastasectomy was 36% or 30.8% ([@ref-19]; [@ref-30]). Few studies have been able to reveal the association between the survival rate of breast cancer patients with lung metastases and various molecular subtypes. However, our study identified that patients with HR+/HER2+ subtype showed the longest OS, and the 5-year survival rate was up to 30.2%. These findings were similar to a previous report on metastatic breast cancer ([@ref-18]). We found that the triple-negative subtype had the worst prognosis, and its 5-year survival rate was only 5.6%. [@ref-28] found that only 23% of patients with metastatic breast cancer of the triple-negative subtype survived 2 years or longer. The great differences in prognoses observed in all tumor subtypes demonstrates that breast cancer is a heterogeneous disease. In our study, we saw that patients with lung metastases only showed a lower risk of death than cases with four metastatic sites at initial diagnosis, indicating that there is a significant reduction in OS as the number of involved sites increases. Our findings were similar to previous reports on the impact of metastatic sites on the OS of breast cancer patients ([@ref-17]). Additionally, some comprehensive studies of four metastatic sites (bone, lung, liver and brain) suggested that patients with brain metastases had significantly poor survival when compared with patients with other metastases ([@ref-11]; [@ref-17]; [@ref-29]).

Our results revealed that older age, black race, advanced tumor grade, triple-negative subtype and number of metastasis sites were all independent risk factors. We also found the hormone receptor status was a vital prognostic factor that should not be ignored. Patients with HR−/HER2+ subtypes did not show a survival advantage when compared with HR+/HER2+ patients. This may be because endocrine therapy plays a significant role in ER-positive patients with breast cancer. Endocrine therapy could improve disease control, symptom relief, and quality of life in most hormone-receptor positive metastatic breast cancer patients ([@ref-8]). Additionally, chemotherapy combined with endocrine therapy could be significantly better than endocrine therapy alone for these patients ([@ref-7]). Chemotherapy is generally used to periodically treat metastatic breast cancer patients with negative hormonal receptors because of its acceptable and reversible toxicity on normal cells ([@ref-8]). Triple-negative breast cancer does not respond to hormone therapy or other available targeted agents, and so chemotherapy became the mainstay in the treatment of patients with breast cancer ([@ref-13]). Because of the unique molecular profile, aggressive behavior of the cancer, and easy relapse in triple-negative patients, more clinical trials are developing and applying targeted drugs, such as epidermal growth factor receptor, vascular endothelial growth factor and poly (ADP-ribose) polymerase (PARP) inhibitors ([@ref-2]; [@ref-3]). We hope more possibilities for a metastatic breast cancer cure can developed in the near future.

Some limitations exist in our research. First, the SEER database does not include information on disease recurrence or subsequent lung metastases. Thus, we could only depict the presence or absence of lung metastases at initial diagnosis, and not comment on patients who developed lung metastases during disease progression. Second, our study was not able to investigate the impact of lung-directed treatment (such as pulmonary metastasectomy or endocrine therapy) on the prognoses of patients, because the public SEER database does not provide this information. Further studies using alternative data should be performed to address this significant point. Third, other metastasis sites such as lymph nodes, peritoneum, pleura or skin which may be helpful in analyzing the prognoses of metastatic breast cancer, were not collected in our study. Fourth, the retrospective nature of the study has an inherent bias.

Conclusions
===========

Our research provides crucial insight into the incidence, prognostic assessment, and risk stratification of breast cancer with lung metastases, enriching the study of the epidemiology of this occurrence. The tumor molecular subtypes and specific sites of extrapulmonary metastases could be used for prognostic evaluation in other prospective studies, and will provide guidance in the early diagnosis and effective treatment of lung metastases in breast cancer.
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